9KH4 | pdb_00009kh4

Crystal structure of Galectin-8 N-CRD with N-acetyllactosamine


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.75 Å
  • R-Value Free: 
    0.212 (Depositor), 0.212 (DCC) 
  • R-Value Work: 
    0.178 (Depositor), 0.179 (DCC) 
  • R-Value Observed: 
    0.182 (Depositor) 

Starting Model: experimental
View more details

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.0 of the entry. See complete history


Literature

Galectin-8 binding to alpha-1 antitrypsin is a physiological mechanism in healthy individuals but exacerbates the symptoms of alpha-1 antitrypsin deficiency.

Sayed, H.Mayo, K.H.Zhou, Y.Tai, G.Su, J.

(2025) Arch Biochem Biophys 772: 110577-110577

  • DOI: https://doi.org/10.1016/j.abb.2025.110577
  • Primary Citation of Related Structures:  
    9KH4

  • PubMed Abstract: 

    Alpha-1 Antitrypsin (AAT) is a serine protease inhibitor that protects lung tissue by neutralizing neutrophil elastase. Galectin-8 (Gal-8) is a tandem-repeat galectin with N- and C-terminal carbohydrate recognition domains (CRDs) that bind β-galactoside-containing N-glycans. Both proteins co-localize in pulmonary and circulatory systems, suggesting a physiological interaction. Here, we demonstrate a glycan-dependent binding between Gal-8 and AAT using pull-down assays, mass spectrometry, isothermal titration calorimetry, and size-exclusion chromatography. Importantly, binding of Gal-8 impairs AAT's protease inhibitory activity, with the N-terminal CRD of Gal-8 sufficient to disrupt AAT function. Kinetic analyses show that Gal-8 inhibits AAT and enhances trypsin activity, as evidenced by a decrease in K m and an increase in catalytic efficiency (k cat /K m ). In cell assays, Gal-8 restored trypsin-mediated proteolysis and induced cell detachment in HeLa and CHO cells despite AAT presence, confirming biological relevance. Leveraging this interaction, we developed a lactose-mediated elution method to purify AAT from human and bovine serum using Gal-8 immobilized on Ni-NTA beads. Moreover, a stable CHO cell line expressing recombinant AAT (∼2 g/L) exhibited glycosylation comparable to serum AAT and retained Gal-8 binding. Our findings reveal Gal-8 as a novel modulator of AAT activity and present a glycan-specific strategy for AAT purification, with implications for biotherapeutic production and quality control.


  • Organizational Affiliation
    • Engineering Research Center of Glycoconjugates Ministry of Education, Jilin Provincial Key Laboratory of Chemistry and Biology of Changbai Mountain Natural Drugs, School of Life Sciences, Northeast Normal University, Changchun, 130024, China.

Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Galectin-8150Homo sapiensMutation(s): 0 
Gene Names: LGALS8
UniProt & NIH Common Fund Data Resources
Find proteins for O00214 (Homo sapiens)
Explore O00214 
Go to UniProtKB:  O00214
PHAROS:  O00214
GTEx:  ENSG00000116977 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupO00214
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.75 Å
  • R-Value Free:  0.212 (Depositor), 0.212 (DCC) 
  • R-Value Work:  0.178 (Depositor), 0.179 (DCC) 
  • R-Value Observed: 0.182 (Depositor) 
Space Group: P 43 21 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 49.154α = 90
b = 49.154β = 90
c = 160.77γ = 90
Software Package:
Software NamePurpose
PHENIXrefinement

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History & Funding Information

Deposition Data

  • Released Date: 2025-11-12 
  • Deposition Author(s): Su, J.Y.

Funding OrganizationLocationGrant Number
Not funded--

Revision History  (Full details and data files)

  • Version 1.0: 2025-11-12
    Type: Initial release